A Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users

NCT03757559 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

226

Enrollment

INDUSTRY

Sponsor class

Conditions

Abuse, Drug

Interventions

DRUG: Cebranopadol 100 micrograms
DRUG: Cebranopadol 400 micrograms
DRUG: Hydromorphone hydrochloride 4 milligrams
DRUG: Placebo matching hydromorphone
DRUG: Placebo matching cebranopadol

Sponsor

Tris Pharma, Inc.